Multilocus genetic profiling to empower drug trials and predict brain atrophy()

Designers of clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) are actively considering structural and functional neuroimaging, cerebrospinal fluid and genetic biomarkers to reduce the sample sizes needed to detect therapeutic effects. Genetic pre-selection, howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohannim, Omid, Hua, Xue, Rajagopalan, Priya, Hibar, Derrek P., Jahanshad, Neda, Grill, Joshua D., Apostolova, Liana G., Toga, Arthur W., Jack, Clifford R., Weiner, Michael W., Thompson, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777716/
https://www.ncbi.nlm.nih.gov/pubmed/24179834
http://dx.doi.org/10.1016/j.nicl.2013.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777716/
https://www.ncbi.nlm.nih.gov/pubmed/24179834
http://dx.doi.org/10.1016/j.nicl.2013.05.007

Ejemplares similares